Global S&T Development Trend Analysis Platform of Resources and Environment
World's largest genetics project to tackle deadly diseases launches | |
admin | |
2019-09-11 | |
发布年 | 2019 |
语种 | 英语 |
国家 | 英国 |
领域 | 气候变化 |
正文(英文) | Press release World's largest genetics project to tackle deadly diseases launchesA new ground-breaking project in the fight against life-threatening illnesses has launched today, 11 September 2019. ![]() The £200 million whole genome sequencing project is being created, forming a partnership of pharmaceutical firms and health experts which will examine and sequence the genetic code of 500,000 volunteers at the UK Biobank, based in Stockport. Prime Minister Boris Johnson said:
Genomics research has the potential to create a genuinely predictive, more personalised healthcare system and the UK has a clear desire to seize the opportunities that research in this area offers, which is why the government has committed to carrying out five million analyses of DNA by 2024. The new project aims to improve health through genetic research, improve the prevention, diagnosis and treatment of a wide range of serious and life-threatening illnesses including cancer, heart diseases, diabetes, arthritis and dementia. Business Secretary Andrea Leadsom said:
Health and Social Care Secretary Matt Hancock said:
The UK Biobank recruited 500,000 people aged between 40 and 69 years between 2006 and 2010 from across the country. They have provided blood, urine and saliva samples for future analysis, detailed information about themselves and agreed to have their health followed on an anonymous basis. Much of the sequencing will be by experts at the Wellcome Sanger Institute, based in Cambridge, and the results will help the NHS treat patients better. Through the Biobank research, industry can work with experts to create new treatments and preventative measures which will help those suffering from illnesses and may eventually reveal why some people develop diseases and others do not. Funding for the genome project comes from a consortium formed by the government’s research and innovation agency, UK Research and Innovation (UKRI) with £50 million through the Industrial Strategy Challenge Fund, £50 million from the research organisation, Wellcome. A further £100 million has come from four of the world’s leading biopharmaceutical and healthcare companies Amgen, AstraZeneca, GlaxoSmithKline (GSK) and Johnson & Johnson. The samples will be sequenced in equal numbers at the Wellcome Sanger Institute in Cambridge and the deCOde site in Iceland, from the genome sequencing company, Illumina. Notes to editorsThis follows a shake-up of immigration rules announced by the Prime Minister in August to encourage the world’s top scientists to move to the UK. The government will set out plans in the autumn to significantly boost public R&D funding, provide greater long-term certainty to the scientific community, and accelerate our ambition to reach 2.4% of GDP. The new immigration route enables international students who have successfully completed a course in any subject at undergraduate level or higher to work, or look for work, at any skill level, giving them valuable work experience at the start of their careers. There will be no cap on the number of students who can apply for the new graduate route. Students who start courses in 2020/21 at undergraduate level or above will be able to benefit from the new route. Those on the route will be able to switch onto the skilled work route if they find a job which meets the skill requirement of the route. The new route for international students builds on the already strong offer available, which is why university-sponsored visa applications are at record levels and over 450,000 international students are currently studying in the UK per year. This will boost the government’s plans to increase the number international students by 30% to 600,000 by 2030, as set out in its International Education Strategy. The genome project builds on a £34 million pilot programme funded by the Medical Research Council (MRC) that saw the first 50,000 UK Biobank participants analysed. This pilot or Vanguard project refined the approach needed to complete this globally unique project. All data held by UK Biobank is anonymised and protected. The addition of complete genetic information to the information held by UK Biobank is expected to reveal why some people develop particular diseases and others do not. It may also hold the key to more precise treatments for a range of conditions tailored to the genetic makeup of an individual and help predict and prevent life-changing diseases. Through this research, industry will be able to work with experts to create new products and services which will help those suffering from illnesses. The government funding forms part of the delivery of the Life Sciences Sector deals and the modern Industrial strategy and is funded through the wider £210 million Industrial Strategy Challenge Fund: Data to early diagnosis and precision medicine, administered by UKRI. Sir Mark Walport, Chief Executive of UK Research and Innovation said
Prof Sir John Bell, HMG’s Life Sciences Champion, said:
John Lepore, Senior Vice President, Research at GlaxoSmithKline (GSK) said:
AstraZeneca quote: Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, commented:
Richard Tillyer, PhD, Global Head, Discovery, Product Development & Supply, Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, commented:
NB: Contract entered by Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson David M. Reese, M.D., Executive Vice-President of Research and Development at Amgen said:
Kari Stefansson, CEO of deCODE Genetics, a subsidiary of Amgen, said:
Sara Marshall, Head of Clinical Research and Physiological Sciences at Wellcome, said:
Sir Michael Rawlins, Chair of UK Biobank’s Board said:
Paula Dowdy, Illumina’s Senior Vice President and General Manager, EMEA, said:
About UK BioBankUK Biobank was established by the Wellcome Trust medical charity, Medical Research Council, Department of Health, Scottish Government and the Northwest Regional Development Agency. It has also had funding from the Welsh Government, British Heart Foundation, Cancer Research UK and Diabetes UK. UK Biobank is supported by the National Health Service (NHS). UK Biobank is open to bona fide researchers anywhere in the world, including those funded by academia and industry. The medical research project is a non-profit charity which had initial funding of about £62 million and a subsequent investment over the past 10 years of around £180 million. About the Wellcome Sanger InstituteThe Wellcome Sanger Institute is one of the premier centres of genomic discovery and understanding in the world. It leads ambitious collaborations across the globe to provide the foundations for further research and transformative healthcare innovations. Its success is founded on the expertise and knowledge of its people and the Institute seeks to share its discoveries and techniques with the next generation of genomics scientists and researchers worldwide. About UK Research and InnovationUKRI works in partnership with universities, research organisations, businesses, charities, and government to create the best possible environment for research and innovation to flourish. We aim to maximise the contribution of each of our component parts, working individually and collectively. We work with our many partners to benefit everyone through knowledge, talent and ideas. Operating across the whole of the UK with a combined budget of more than £7 billion, UKRI brings together the seven Research Councils, Innovate UK and Research England.
Published 11 September 2019
|
URL | 查看原文 |
来源平台 | GOV.UK - Department for Business, Energy & Industrial Strategy |
文献类型 | 新闻 |
条目标识符 | http://119.78.100.173/C666/handle/2XK7JSWQ/216303 |
专题 | 气候变化 |
推荐引用方式 GB/T 7714 | admin. World's largest genetics project to tackle deadly diseases launches. 2019. |
条目包含的文件 | 条目无相关文件。 |
个性服务 |
推荐该条目 |
保存到收藏夹 |
查看访问统计 |
导出为Endnote文件 |
谷歌学术 |
谷歌学术中相似的文章 |
[admin]的文章 |
百度学术 |
百度学术中相似的文章 |
[admin]的文章 |
必应学术 |
必应学术中相似的文章 |
[admin]的文章 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论